Changes

no edit summary
Line 2,184: Line 2,184:  
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
 
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
 
|Disease
 
|Disease
|Parastou Tizro, MD (trainee); Celeste Eno, PhD;
+
|Parastou Tizro, MD (trainee); Celeste Eno, PhD
Sumire Kitahara, MD
   
|3/17/2024
 
|3/17/2024
 
|
 
|
Line 2,377: Line 2,376:  
|6/30/24
 
|6/30/24
 
|Pending
 
|Pending
| ||SK|| ||
+
|5/13/24||SK||6/6/24||
 
|Hepatosplenic T-cell Lymphoma
 
|Hepatosplenic T-cell Lymphoma
 
|Michelle Don, MD, MS
 
|Michelle Don, MD, MS
Line 2,387: Line 2,386:     
Sumire Kitahara, MD
 
Sumire Kitahara, MD
| || ||Pending
+
|6/6/24|| ||Pending
 
| ||SK|| ||
 
| ||SK|| ||
 
|Anaplastic Large Cell Lymphoma, ALK-Positive
 
|Anaplastic Large Cell Lymphoma, ALK-Positive
Line 2,401: Line 2,400:  
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
 
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
 
Sumire Kitahara, MD
 
Sumire Kitahara, MD
| || ||Pending
+
|6/6/24|| ||Pending
 
| ||SK|| ||
 
| ||SK|| ||
 
|Anaplastic Large Cell Lymphoma, ALK-Negative
 
|Anaplastic Large Cell Lymphoma, ALK-Negative